"Lao Qi, sit. Shen Qi poured a glass of water for Director Qi.

"Well, your chemistry project C01B, which is a benzoazazazene compound mentioned in the paper published in JACS, has a pharmaceutical company that wants to buy your patent. Director Qi is really the God of Wealth of the center, and he said: "The pharmaceutical company may not dare to directly look for a person as big as you, so they found me." ”

"No problem, we can transfer the patent of C01B, who is the buyer?" asked Shen Qi.

Director Qi said: "The buyer is Lushan Pharmaceutical, which is a subsidiary of Pfizer in China, an American-funded enterprise. ”

Shen Qi said "oh": "Pfizer's subsidiary, it's a little interesting." ”

Director Qi, who is proficient in law and business operations, said: "I have a general understanding of the situation, your C01B is said to be similar to Pfizer's smoking cessation drug Qubishi in 97, and the administrative protection of Bishi in China has expired, which means that the patent of this smoking cessation drug has expired. When I was a student in the United States, I specialized in the operation of Pfizer, and in the last 20 years, Pfizer has invested a lot of manpower, material and financial resources in acquisitions. ”

The current situation of chemical drugs in China is that once the patents of marketed patented drugs expire, a large number of generic drugs will emerge. As a result, generic drugs account for more than 90% of China's chemical drug market.

There are pros and cons, generic drugs that are almost the same as the efficacy of the original drug are relatively cheap and can be afforded by ordinary people.

However, from the perspective of the long-term development of China's pharmaceutical industry, the disadvantages outweigh the advantages.

Most of China's pharmaceutical companies blindly imitate, resulting in very weak core R&D capabilities and almost losing their innovation capabilities.

The pharmaceutical industry is a technology-led industry, and pharmaceutical companies without scientific and technological innovation capabilities will not be able to become bigger and stronger, or even survive after all.

There are too many generic drugs of the same type, and pharmaceutical companies begin to fight a price war.

Many small and medium-sized pharmaceutical companies in China specialize in the production of generic drugs, and in the fierce competition and even chaotic price wars, most of them lose money all year round, go out of business at a loss, or are acquired by large pharmaceutical groups.

Another big market for generic drugs is India, where a pharmaceutical company, Aurobindo, specializes in generic Pfizer's patented drugs, and the quality of the generic drugs is so high that even the FDA has approved it.

The Indian pharmaceutical company has copied more than 100 of Pfizer's patented drugs, 39 of which have been granted the right to operate in the U.S. market.

The U.S. advocates global trade, fair competition, and opposes monopolies, at least the U.S. government is fair and just to Indian companies.

The drug patent expires, people have the right to imitate it, and Pfizer can't go to court.

In the case studied by Director Qi, Pfizer changed its operating model, and since it could not crack down on copycat factories, Pfizer acquired Aurobindo, an Indian pharmaceutical company that had devoted its life to imitating them.

At the same time, Pfizer's wholly-owned subsidiary, Greenstone Pharmaceuticals, is buying a large number of generic drugs after the patent expires around the world.

The current operating model of Pfizer, the deep-pocketed pharmaceutical giant, is to maintain the core competitiveness of independent research and development of new drugs, and simultaneously acquire generic drug companies and generic drugs.

The business of Greenmountain Pharmaceutical, a subsidiary of Pfizer in China, is similar to that of Greenstone in the United States, which is just three words: buy, buy, buy.

Shen Qi said: "So in Pfizer's opinion, our C01B imitates their rings?"

Director Qi explained: "The patent bill for drugs is very complex and difficult to explain. To put it simply, the same drug can also apply for different patents due to different preparation methods, which belongs to patents in terms of technical processes. ”

Shen Qi has also learned the rules of the game in the pharmaceutical industry during this time, and there is a senior person in his family who is his doctor's mother.

Since the mid-20th century, the research and development of chemical drugs has been advancing greatly thanks to the development of chemical science. Some of the new compounds were quickly identified in the laboratory and applied to clinical research.

After decades of development, the research and development of chemical drugs is becoming more and more complex and long, involving not only chemistry, but also biology, medicine, information science (computer-aided), materials science and other knowledge.

At present, it takes an average of 12 years for a new drug to go from initial laboratory research to market.

According to the World Health Organization, only 5 of the 5,000 compounds that have undergone preclinical trials make it to subsequent clinical trials.

Only one of these compounds will be given final approval for marketing.

A complete set of new compound research and development cycle is more than 10 years, with an average cost of billions of dollars, and it is very normal for international pharmaceutical giants or large CROs to have more than 100 professionals in their research teams and testing teams for a single compound, and the processes involved are extremely cumbersome and complex.

Shen Qi can only do the stage of synthesizing samples and animal experiments in the laboratory, and his center is not in a position to complete a full set of drug development, testing, and improvement work for the time being: "I decided to sell the patent of C01B. ”

Director Qi reminded: "The Americans' bid will not be too high. ”

Shen Qi nodded and said, "I understand, my C01B has not done any experiments, not even animal experiments." Since Greenmountain Pharmaceutical dares to buy it, then I dare to sell it. ”

Compounds that have been tested in preclinical trials can enter the clinical phase I to test whether the compounds are toxic or other dangerous side effects to normal healthy people, and this promotion rate is only 1 in 1,000.

After the clinical phase I, there are II~IV, and the uncertainty is too high.

Shen Qi and Lao Yan are crookedly synthesizing C01B, not to mention clinical, and they have not even done animal experiments.

Whether C01B has any real value or not will take many years to determine.

At this stage, some people dare to buy the laboratory compound C01B, which requires strong prediction and has a gambling component.

Drug discovery is an industry full of drama.

In 1968, the R&D team of Ragan successfully synthesized a new compound, sevoflurane, in an experiment, and they observed that the sevoflurane decomposition product had a certain degree of renal toxicity in a high temperature test at 210 degrees Celsius.

As a result, the American developers decided that sevoflurane had no future and sold its patent to Maruishi in Japan at a very low price.

The Maruishi company is stealing fun, and they are like a treasure.

In 1993, Maruishi Corporation launched an improved version of sevoflurane, which was first marketed in Japan under the trade name Ultane.

In nearly 2 million clinical observations, sevoflurane has shown excellent efficacy and safety, and it has subsequently been marketed in dozens of countries such as China, the United States, and South Korea.

The Chinese trade name of sevoflurane is Kettery, which is an inhaled general anesthetic that is used in many hospitals in China when operating on patients.

Compounds, which have no future in the eyes of American researchers, have become treasures in the hands of Japanese pharmacologists, and this is the drama of the drug development industry.

Of course, the cycle of turning waste into treasure is quite long, and it took Marushi a full 25 years to make sevoflurane an excellent anesthetic recognized by the medical community.

Not to mention 25 years, Shen Qi doesn't even want to wait for 5 years, the purpose of his entry into the chemical industry is not to develop smoking cessation drugs, C01B is just an unexpected gain: "Then please Director Qi, I mean C01B can be sold, and the patent transfer price will be negotiated with the other party by Director Qi in accordance with the rules." ”

In response to the old saying, mathematics and physics are the fire that shows the way, and chemistry and biology are the crematoriums and the pits where science students are buried.

Shen Qi lit the fire and lit the lamp.

Now that Shen Qi has entered the pit, this is the fate of science students.

Playing biochemistry is really a very complicated project, and Shen Qi is most comfortable with mathematics, physics and politics.

Because of Director Qi's temporary visit, Shen Qi only wrote a side story on condensed matter physics before getting off work at 5 o'clock.

"Today I'm working overtime and going home by 10 o'clock. Shen Qi sent a message to Ou Ye, and he wanted to finish the other two physics side stories in one go.

There are a total of four articles in mathematics and physics, and if all of them are published, Shen Qi predicts that he will be able to save enough points for students to upgrade to 15 levels in mathematics.

Ou Ye replied to the message: "Go home for dinner first, and then work overtime after eating." ”

Academician Shen's villa is very close to Yanda, and it is only a ten-minute walk.

The wife of heaven and earth is the biggest, and the wife orders to go home for dinner, so she must go home for dinner.

Shen Qi went home to eat, after eating, teasing the baby, and adding a ghost class, I don't want to work overtime.

The next day, Shen Qi finished writing all the side stories, sent them to the relevant mathematics and physics journals, and then reviewed the documents that needed his confirmation.

The reason why the leader of a scientific research institution or scientific research team is called a boss is because the bosses are busy with business and have a lot of paperwork to deal with with the boss.

Especially to be a Ben-level boss, his signature may involve tens of millions or even hundreds of millions of scientific research funds.

Researchers with the title of associate professor or above are eligible to apply for scientific research projects separately.

After receiving the training of the principal of the party school, Shen Qi is very cautious about applying for large amounts of scientific research funds.

It doesn't matter if the project is less than 1 million, Shen Qi approved it easily.

Shen Qi must strictly control more than 1 million theoretical research projects and more than 10 million applied projects.

Associate Professor Xiao Junlong submitted an application for a mathematics project, and the application fund was 986,327 RMB, with zero and round, and the list was clearly detailed.

"Stuck valves, Lao Xiao, you have studied me very thoroughly. Shen Qi's hand holding the pen didn't sign for a long time, and these people under him were all fine.